A skilled surgeon and renowned researcher in locally advanced and metastatic breast cancer, Dr. Roshni Rao provides expertise in early stage breast cancer, innovative localization techniques, and tumescent mastectomy.

Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute to improve the detection and treatment of aggressive prostate cancer (PCa).

Searching for approaches to address ongoing challenges, a number of studies and clinical trials are evaluating new approaches for neoadjuvant therapies and early phase clinical trials to assess novel therapeutic agents based on tumor genomics.

In the past 50 years, use of neoadjuvant chemotherapy for breast cancer has evolved. Today, clinicians at NewYork-Presbyterian are using neoadjuvant therapy to tackle residual tumor.

Surgeons at NewYork-Presbyterian/Columbia are turning up the heat (or cold as the case may be) on early-stage breast cancer tumors with the use of ablation therapies.

Charles G. Drake was presented with a unique opportunity to build a genitourinary cancer group with the focus on trying to cure these cancers with the immune system.

The promise of immunotherapy is altering how many cancers are perceived and treated, but it has so far eluded the treatment for some of the more aggressive malignancies, including ovarian cancer.